ERRATUM

Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Pere Gascón¹ • Matti Aapro² • Heinz Ludwig³ • Carsten Bokemeyer⁴ •
Mario Boccadoro⁵ • Matthew Turner⁶ • Kris Denhaerynck⁷ • Karen MacDonald⁷ •
Ivo Abraham^{7,8}

Published online: 19 October 2015
© Springer-Verlag Berlin Heidelberg 2015

Erratum to: Support Care Cancer
DOI 10.1007/s00520-015-2861-z

Table 1 footer definition for “advanced disease” (footer d) should read: d Stage 4 (Stage 3 if multiple myeloma) and prior chemo in metastatic setting

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00520-015-2861-z>.

✉ Ivo Abraham
abraham@pharmacy.arizona.edu

¹ Division of Medical Oncology, Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain

² Institut Multidisciplinaire d’Oncologie, Clinique de Genolier, Genolier, Switzerland

³ Medizinische Abteilung I-Onkologie und Haematologie, Wilhelminenspital, Wien, Austria

⁴ Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany

⁵ Dipartimento di Oncologia e Ematologia, Azienda Ospedaliero, Universitaria S. Giovanni Battista di Torino, Torino, Italy

⁶ Sandoz Biopharmaceuticals, Holzkirchen, Germany

⁷ Matrix45, Tucson, AZ, USA

⁸ Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Drachman Hall B306H, 1295 N Martin, Tucson, AZ 85721, USA